Update: Modern Approaches to the Treatment of Localized Esophageal Cancer

详细信息    查看全文

• 作者：James Welsh (1)
  Arya Amini (2)
  Anna Likhacheva (1)
  Jeremy Erasmus J. (3)
  Daniel Gomez (4)
  Marta Davila (5)
  Reza J. Mehran (6)
  Ritsuko Komaki (1)
  Zhongxing Liao (1)
  Wayne L. Hofstetter (6)
  Jeffrey Lee H. (5)
  Manoop S. Bhutani (5)
  Jaffer A. Ajani (7)
  
• 关键词：Esophageal cancer ; Diagnosis ; Minimally invasive treatments ; Chemoradiation ; Intensity ; modulated radiation therapy ; Photon therapy ; Proton beam therapy
• 刊名：Current Oncology Reports
• 出版年：2011
• 出版时间：June 2011
• 年：2011
• 卷：13
• 期：3
• 页码：157-167
• 全文大小：423KB
• 参考文献：1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137鈥?0. CrossRef
  2. Surveillance Epidemiology and End Results, National Cancer Institute. SEER Stat Fact Sheets: Esophagus. Available at http://seer.cancer.gov/statfacts/html/esoph.html (access verified December 15, 2010)
  3. American Cancer Society. Cancer Facts & Figures聽2010. Atlanta: American Cancer Society; 2010. available at http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. (access verified December 15, 2010)
  4. Brown LM, Swanson CA, Gridley G, et al. Dietary factors and the risk of squamous cell esophageal cancer among black and white men in the United States. Cancer Causes Control. 1998;9:467鈥?4. CrossRef
  5. Islami F, Kamangar F, Aghcheli K, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer. 2004;90:1402鈥?. CrossRef
  6. Jonge PJ DE, Wolters LM, Steyerberg EW, et al. Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in a Dutch cohort. Aliment Pharmacol Ther. 2007;26:31鈥?. CrossRef
  7. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184鈥?. CrossRef
  8. Rice TW, Rusch VW, Ishwaran H, Blackstone EH. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union against Cancer Cancer Staging Manuals. Cancer. 2010;116:3763鈥?3. CrossRef
  9. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894鈥?02. CrossRef
  10. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507鈥?2. CrossRef
  11. 鈥?Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol. 2008; 14:1479鈥?0. / This study helps to establish the utility of using endoscopic ultrasonography for esophageal cancer staging. CrossRef
  12. 鈥?van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008; 98:547鈥?7. / This study helps to establish the utility of using endoscopic ultrasonography for esophageal cancer staging. CrossRef
  13. Lowe VJ, Booya F, Fletcher JG, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005;7:422鈥?0. CrossRef
  14. Pfau PR, Perlman SB, Stanko P, et al. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography. Gastrointest Endosc. 2007;65:377鈥?4. CrossRef
  15. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 2006;82:391鈥?. discussion 394-5. CrossRef
  16. Rizk N, Downey RJ, Akhurst T, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006;81:1076鈥?1. CrossRef
  17. Little SG, Rice TW, Bybel B, et al. Is FDG-PET indicated for superficial esophageal cancer? Eur J Cardiothorac Surg. 2007;31:791鈥?. CrossRef
  18. Mamede M, Abreu ELP, Oliva MR, et al. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007;30:377鈥?8. CrossRef
  19. 鈥?Bolton WD, Hofstetter WL, Francis AM, et al. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009; 138:831鈥?. / This study establishes the prognostic significance of tumor length. CrossRef
  20. 鈥?Yendamuri S, Swisher SG, Correa AM, et al. Esophageal tumor length is independently associated with long-term survival. Cancer 2009; 115:508鈥?6. / This study establishes the prognostic significance of tumor length. CrossRef
  21. Okada M, Murakami T, Kumano S, et al. Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med. 2009;23:73鈥?0. CrossRef
  22. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805鈥?2. CrossRef
  23. Katsoulis IE, Wong WL, Mattheou AK, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study. Int J Surg. 2007;5:399鈥?03. CrossRef
  24. Meyers BF, Downey RJ, Decker PA, et al. The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg. 2007;133:738鈥?5. CrossRef
  25. van Westreenen HL, Westerterp M, Sloof GW, et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg. 2007;94:1515鈥?0. CrossRef
  26. Ell C, May A, Pech O, Gossner L, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett鈥檚 cancer). Gastrointest Endosc. 2007;65:3鈥?0. CrossRef
  27. 鈥?Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Stepwise circumferential and focal ablation of Barrett鈥檚 esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40:359鈥?9. / This study helps to demonstrate the outcomes of circumferential and focal ablation for the treatment of Barrett鈥檚 esophagus. CrossRef
  28. Gondrie JJ, Pouw RE, Sondermeijer CM, et al. Effective treatment of early Barrett鈥檚 neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008;40:370鈥?. CrossRef
  29. 鈥?Sharma VK, Jae Kim H, Das A, et al. Circumferential and focal ablation of Barrett鈥檚 esophagus containing dysplasia. Am J Gastroenterol. 2009; 104:310鈥?. / This study helps to demonstrate the outcomes of focal ablation for the treatment of Barrett鈥檚 esophagus. CrossRef
  30. 鈥?Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett鈥檚 esophagus with dysplasia. N Engl J Med. 2009; 360(22):2277鈥?8. / This study demonstrates in a randomized fashion the benefits of radiofrequency ablation for the treatment of Barrett鈥檚 esophagus. CrossRef
  31. 鈥?Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett鈥檚 esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009; 70:635鈥?4. / This study demonstrates in a randomized fashion the benefits of cryospray for the treatment of Barrett鈥檚 esophagus. CrossRef
  32. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett鈥檚 esophagus with high-grade dysplasia. Gastrointest Endosc. 71:680鈥?.
  33. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25:3719鈥?5. CrossRef
  34. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161鈥?. CrossRef
  35. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462鈥?. CrossRef
  36. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305鈥?3.
  37. Ellis Jr FH, Gibb SP, Watkins Jr E. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the esophagus and cardia. Ann Surg. 1983;198:531鈥?0. CrossRef
  38. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662鈥?. CrossRef
  39. 鈥?Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD. Outcomes after transhiatal and transthoracic esophagectomy for cancer. Ann Thorac Surg. 2008;85:424鈥?. / This study provides an update from the Surveillance, Epidemiology, and End Results database suggesting a survival advantage to the transhiatal esophagectomy surgical technique. CrossRef
  40. Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys. 1989;16:329鈥?4. CrossRef
  41. Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 1989;17:49鈥?4. CrossRef
  42. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623鈥?. CrossRef
  43. Sun XD, Yu JM, Fan XL, et al. [Randomized clinical study of surgery versus radiotherapy alone in the treatment of resectable esophageal cancer in the chest] (article in Chinese). Zhonghua Zhong Liu Za Zhi. 2006;28:784鈥?.
  44. 鈥?Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244鈥?0. / This study shows the benefits of postoperative radiation following surgery versus surgery alone. CrossRef
  45. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593鈥?. CrossRef
  46. al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15:277鈥?4.
  47. Smith TJ, Ryan LM, Douglass Jr HO, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:269鈥?6.
  48. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979鈥?4. CrossRef
  49. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727鈥?3.
  50. 鈥?Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27:5062鈥?. / This update from the large study conducted by the UK Medical Research Council [49] demonstrates limited impact of preoperative chemotherapy on overall survival. CrossRef
  51. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study鈥揓COG9204. J Clin Oncol. 2003;21:4592鈥?. CrossRef
  52. Coia LR. Chemoradiation: a superior alternative for the primary management of esophageal carcinoma. Semin Radiat Oncol. 1994;4:157鈥?4. CrossRef
  53. Gill PG, Denham JW, Jamieson GG, et al. Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol. 1992;10:1037鈥?3.
  54. Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys. 1991;20:29鈥?6. CrossRef
  55. 鈥?Abrams JA, Buono DL, Strauss J, et al. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer 2009; 115:4924鈥?3. / This study showed worse outcomes with chemoradiation in terms of disease-specific survival when compared to surgery in elderly patients. CrossRef
  56. Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167鈥?4. CrossRef
  57. 鈥?Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. Int J Radiat Oncol Biol Phys 2011, in press. / This study shows most patients receiving definitive chemoradiation therapy recur within the GTV, suggesting that local disease control continues to be a problem with the current radiation doses.
  58. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097鈥?05. CrossRef
  59. Martel MK, Ten Haken RK, Hazuka MB, et al. Estimation of tumor control probability parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999:31鈥?7.
  60. Kong F-M, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys. 2005;63:324鈥?3. CrossRef
  61. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6:659鈥?8. CrossRef
  62. 鈥?Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086鈥?2. / This phase 3 study demonstrates the benefit of median and overall survival in multimodality therapy compared to surgery alone. CrossRef
  63. 鈥?Gaast A, van Hagen P, Hulshof M, Richel D, et al. for the CROSS Study Group. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study (abstract 4004). J Clin Oncol. 2010; 28(15S):302S. / This study presented in abstract form also showed benefit in median and overall survival in patients receiving multimodality therapy compared to surgery alone.
  64. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226鈥?4. CrossRef
  65. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725鈥?0. CrossRef
  66. 鈥?Adelstein DJ, Rice TW, Rybicki LA, et al. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol. 2009; 4:1264鈥?. / This study looked at patients with a high risk for distant failure and showed adjuvant chemoradiation to be beneficial in preventing recurrence. The regimen was also tolerable for patients. CrossRef
  67. Marks LB, Ma J. Challenges in the clinical application of advanced technologies to reduce radiation-associated normal tissue injury. Int J Radiat Oncol Biol Phys. 2007;69:4鈥?2. CrossRef
  68. 鈥?Welsh J, Riley B, Palmera M, Amina M, Komakia R, Gomez D, Liao Z, Hofstetter W, Ajani J, Cox J. Intensity modulated proton therapy allows dose escalation and normal-tissue sparing in locally advanced distal esophageal tumors (abstract). Int J Radiat Oncol Biol Phys. 2010; 78(3 Suppl 1):S808. / This study showed the potential benefit of proton therapy compared to photon treatment in reducing the amount of radiation to normal lung, heart, and liver.
  69. 鈥?Guo X, Liao Z, Komaki R, Wen H, Chang JY, O鈥橰eilly MS Jeter M, Bucci MK, Cox JD. Concurrent chemotherapy and proton beam therapy for esophageal cancer (abstract). Int J Radiat Biol. 2009; 75:S289鈥?0. / The early results in this study show proton therapy to have higher complete pathologic response and less severe side effects compared to intensity-modulated radiation therapy.
  70. Sugahara S, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys. 2005;61:76鈥?4. CrossRef
  71. Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol. 186:482鈥?.
  
• 作者单位：James Welsh (1)
  Arya Amini (2)
  Anna Likhacheva (1)
  Jeremy Erasmus J. (3)
  Daniel Gomez (4)
  Marta Davila (5)
  Reza J. Mehran (6)
  Ritsuko Komaki (1)
  Zhongxing Liao (1)
  Wayne L. Hofstetter (6)
  Jeffrey Lee H. (5)
  Manoop S. Bhutani (5)
  Jaffer A. Ajani (7)
  
  1. Division of Radiation Oncology, Unit 97, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  2. University of California, Irvine, University Drive, Irvine, CA, 92697, USA
  3. Department of Diagnostic Radiology, Unit 1478, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  4. Department of Radiation Oncology, Unit 1150, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  5. Department of Gastroenterology, Hepatology, and Nutrition, Unit 1466, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  6. Department of Thoracic and Cardiovascular Surgery, Unit 1489, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  7. Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
  

文摘

The optimal treatment strategy for esophageal cancer continues to be a topic of debate. Improvements in chemotherapy drugs, surgical techniques, and radiotherapy planning and delivery have led to the design of treatment approaches that are specific to both the stage of the tumor and the overall performance status of the patient. Surgery continues to be the standard treatment option for localized disease, but multimodality treatments that include radiation and chemotherapy with surgery are increasingly used. The next few years will continue to see improvements in radiation techniques, especially proton beam treatment; the development of additional minimally invasive surgical approaches to minimize postoperative side effects; and the discovery of molecular biomarkers to help specifically target treatment of esophageal cancer in individual patients.